key: cord-0896017-wgc6ch47
authors: Emmenegger, M.; De Cecco, E.; Lamparter, D.; Jacquat, R. P. B.; Ebner, D.; Schneider, M. M.; Condado Morales, I.; Schneider, D.; Dogancay, B.; Guo, J.; Wiedmer, A.; Domange, J.; Imeri, M.; Moos, R.; Zografou, C.; Trevisan, C.; Gonzalez-Guerra, A.; Carrella, A.; Dubach, I. L.; Xu, C. K.; Meisl, G.; Kosmoliaptsis, V.; Malinauskas, T.; Burgess-Brown, N.; Owens, R.; Mongkolsapaya, J.; Hatch, S.; Screaton, G. R.; Schubert, K.; Huck, J. D.; Liu, F.; Pojer, F.; Lau, K.; Hacker, D.; Probst-Mueller, E.; Cervia, C.; Nilsson, J.; Boyman, O.; Saleh, L.; Spanaus, K.; von Eckardstein, A.; Schaer, D. J.; Ban,
title: Population-wide evolution of SARS-CoV-2 immunity tracked by a ternary immunoassay
date: 2020-06-02
journal: nan
DOI: 10.1101/2020.05.31.20118554
sha: dcf57e3a2951cde19d67d8078f9828e786f23d62
doc_id: 896017
cord_uid: wgc6ch47

Serological assays can detect anti-SARS-CoV-2 (SARS2) antibodies, but their sensitivity often comes at the expense of specificity. Here we used a Ternary Automated Blood Im-munoassay (TRABI) to assess the IgG response against SARS2 in 3,815 prepandemic plasma samples and 126 virologically and/or clinically confirmed COVID-19 samples. Posterior probabilities were calculated from 3x8 measurements of logarithmically diluted samples against the ectodomain and the receptor-binding domain of the spike protein and the nucleoprotein. We then performed 429,624 assays on 17,901 blood samples from patients of the University Hospital Zurich and from healthy blood donors. We found se-ropositivity in 44 of 8,591 patients and in 26 of 5,388 blood donors from December 2019 to May 2020. Western blotting confirmed seropositivity in COVID samples but in none of the prepandemic samples. Solution-equilibrium measurements revealed immunodominant antibodies with nanomolar affinity in COVID samples, whereas prepandemic plasma showed lower affinities despite similar titers for individual SARS2 antigens. Hence, TRABI identifies seropositive individuals in large unselected cohorts, discriminates be-tween SARS2 immunity and low-affinity crossreactivity, and is therefore suitable for large-scale nationwide screening campaigns.

Within just a few months of the onset of the SARS-CoV-2 (henceforth SARS2) pandemic, several million cases and hundreds of thousands of fatalities from Corona Virus Disease (COVID) have been registered. It has also indirectly caused many more deaths by hijacking healthcare resources, thereby making them unavailable to patients suffering from other diseases. In addition, 5 COVID has created profound economic distress for most travel-related industries. Finally, it has disrupted a plethora of industrial supply chains, resulting in a massive worldwide unemployment crisis that will undoubtedly cost many more human lives.

In order to alleviate the direct consequences of the SARS2 pandemic, governments and public healthcare agencies need granular and reliable data on the prevalence of infection, the incidence 10 of new infections, and the spatial-temporal oscillations of these parameters within regions of interest. The acquisition of such data, however, is daunting and data are prone to misinterpretation [1] . Firstly, data needs to be acquired extremely rapidly. Secondly, their usefulness is dependent on being representative of large populations, meaning that they need to be acquired in massive numbers. Finally, the tolerance of false-positives and false-negatives must be extremely low in 15 order to ensure an accurate estimation of the prevalence.

Intuitively, PCR-based diagnostics would seem suitable to fulfill the above criteria. However, practical experience has shown that this is not the case. The acquisition of representative diagnostic material for PCR has proven challenging, with deep nasal swabs being difficult to perform, uncomfortable for patients and potentially hazardous for medical personnel. Accordingly, the sensi-20 tivity of PCR diagnostics is often disappointing, with reported false-negative rates of 25% even under the best conditions [2] .

Serological assays, on the other hand, address the adaptive immune responses of the host which are fundamental to limiting viral spread within individuals and populations. While they lag behind the viral infection, they can serve as both powerful epidemiological tools as well as useful clinical 25 aids. Firstly, antibodies can be easily retrieved from many biological fluids, notably including venous and capillary blood. Secondly, antibodies typically persist for several months whereas the viral load in the upper respiratory tract frequently wane within weeks [3] . Importantly, immunological assays can be largely automated, and are thus suitable to mass screening of extremely large cohorts. This aspect is crucial since it provides a reliable readout of degree of immunity in a pop-30 ulation, which is necessary for responsible easing of social restriction measures.

Representative testing of entire populations mandates fully automatable assays capable of outputting reliable results at extremely high rates and very low cost. Here we describe an assay that . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 2, 2020. . https://doi.org/10.1101/2020.05.31.20118554 doi: medRxiv preprint fulfills these criteria. We have screened 17,901 samples for antibodies against three SARS2related antigens: the ectodomain of the spike protein (S), its receptor-binding domain (RBD) and the nucleocapsid protein (NC), using SARS2 enzyme-linked immunoassays (ELISA) [4] [5] [6] . Samples included patients entering the University Hospital of Zurich (USZ) from December 2019 to the present (defined as "copandemic"; n=8'591), a cohort of patients treated at USZ between 5 2016 and 2018 ("prepandemic"; n=2'719), as well as 1'096 prepandemic and 5'388 copandemic samples from blood donors in Zurich and Lucerne. Our test cohorts were completed by wellannotated virologically and/or clinically confirmed patients with SARS2 infections (75 for USZ and 51 samples for blood donors). Our results paint a detailed picture of the spread of the pandemic within the greater Zurich area, and may be representative of other metropolitan areas with a highly 10 mobile population served by large international airports.

. CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 2, 2020. . https://doi.org/10.1101/2020.05.31.20118554 doi: medRxiv preprint

For the detection of seroconversion in tens of thousands of individuals who potentially acquired an infection with SARS2, it was crucial to maximize the specificity and sensitivity of our assay.

Another paramount consideration was the ability to maintain a throughput of >4'000 samples/24h 5 and minimize the costs of reagents and labor. We achieved these goals (1) by testing for multiple viral antigens, (2) by employing extensive automation including contactless fluid-handling, (3) by vastly reducing the reagent volumes and (4) by adopting advanced statistical techniques for data interpretation.

TRABI utilizes acoustic dispensing [7] to transfer nanoliter amounts of plasma into high-density 10 1536-well plates (total assay volume: 3 µl) and measures the IgG response against the SARS2 spike protein (S, amino acids 1-1208, constituting the ectodomain of the protein which initiates the interaction with ACE2 [8] ), the receptor binding domain (RBD, amino acids 330-532), and the nucleocapsid protein (NC, amino acids 1-419) (Fig. 1A) . Each sample was tested at eight consecutive two-fold dilution points (1:50 to 1:6400), and the resulting data were fitted to a sigmoidal 15 curve by logistic regression. The inflection point (or -log(EC50)) of each sigmoid was defined as the respective antibody titer.

As reference samples for assay establishment, we utilized a collective of 56 venous plasma samples drawn at various days post onset of symptoms (dpo) from 27 RT-qPCR confirmed patients suffering from COVID-19 and hospitalized at the University Hospital of Zurich (USZ, true posi-20 tives), as well as 90 anonymized USZ samples from the prepandemic era (true negatives) (see Table S1 ). We then constructed receiver operating characteristic (ROC) curves to assess the assay quality for each antigen individually. Finally, we created a composite metric that integrates S/RBD/NC measurements using quadratic discriminant analysis (QDA). While each single antigen showed an excellent discrimination of negatives and positives on samples drawn at ≥14 dpo, 25 the QDA model outperformed the individual antigen measurements at 7-13 dpo, where the emergence of an IgG response is expected to be variable (Fig. 1B) . We therefore used the QDA modeling assumptions to infer the prevalence in large cohorts based on the distributional information of true negatives and true positives (details in Methods) using information gained from all three antigens. 30

To benchmark TRABI, we compared the results with an in-house high-throughput assay under development at the University of Oxford (optimizations ongoing at the time of data acquisition), the Roche Elecsys, the DiaSorin, the EuroImmun, and the Abbott systems (Fig. 1C) , using 139 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted June 2, 2020. . https://doi.org/10.1101/2020.05.31.20118554 doi: medRxiv preprint of 149 samples (10 were removed from the analysis because of insufficient sample volume to perform all tests). While TRABI scored best at early time points compared to others, all the assays used for comparison performed equally well, with 100% specificity at 100% sensitivity as assessed by this dataset of clearly limited size. We then plotted the samples drawn at multiple dpo for all individuals to assess the evolution of the IgG response. The results revealed a temporal 5 pattern consistent with the gradual emergence of IgG antibodies within 14 dpo (Fig. 1D) . The To estimate the prevalence of SARS2 seropositivity in the population, sequential samples (prepandemic, December 2019 -May 2020 (copandemic)) from two cohorts were analyzed using a high-throughput microELISA approach we call TRABI. IgG antibodies against S, the RBD, and the NC were examined and the -log(EC50) was determined. B. Using 56 samples from RT-qPCR and clinically confirmed SARS2-infected patients and 90 samples from the prepandemic era, we assessed the specificity-sensitivity relationship of TRABI, for all antigens individually and using a QDA-based posterior probability by combining results from all antigens into a single score. While at 7 ≤ dpo ≤ 13, the assay relying on the rise of an IgG response had a limited sensitivity of approximately 60% at 100% specificity using the posterior probability or S, we reached 100% sensitivity for samples ≥ 14 dpo. C. COVID and prepandemic samples were used to assess the performance of TRABI, commercial tests (Roche, DiaSorin, Abbott, Euroimmun) and an early version of an assay under development at the Target Discovery Institute (Oxford). While all tests scored equally at ≥14 dpo, TRABI outperformed other assays at ≤13 dpo. D. Time course of IgG response in 56 samples from 27 COVID patients. IgG antibodies were reliably detectable at ≥13 dpo. Colors represent individual patients.

. CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted June 2, 2020. . https://doi.org/10.1101/2020.05.31.20118554 doi: medRxiv preprint performance and throughput described above indicate that TRABI is suitable to investigate the prevalence of seroconversion at population scale.

Due to supply-chain bottlenecks, but also because of the intrinsically narrow window of infectivity, testing of individuals for the presence of SARS2 nucleic acids is currently limited to those at ele-5 vated risk. In Switzerland, individuals with mild symptoms were asked to isolate at home, often without being tested for the presence of SARS2 RNA. Thus, the true number of people who underwent an infection with SARS2 may at best be a rough estimate modelled on data of PCRconfirmed cases and numbers of hospitalizations [9, 10]. We are therefore using TRABI to screen a large sample of Swiss urban populations. To date, we have screened 17,901 samples from a 10 university hospital (USZ) cohort of individuals with diverse diseases (Table S1 ) and from the blood donation service (BDS, see Table S1 ) of Zurich and Lucerne (healthy group), starting from December 2019 (Fig. S1A, B) .

To reliably measure the prevalence of seroconversion, we used known positives and negatives as internal calibrators for each cohort. We tested two models: the first model assumes that both 15 the condition-positive and negative data follow distinct multivariate Gaussian distribution ( Fig. 2A,   B) , whereas the second model assumes that condition-negative data follow a multivariate t distribution while condition positive follow again a Gaussian distribution (Fig. S1C, D) . Within the USZ cohort, we queried the clinical records of all screened samples for the word "COVID" in anamnestic reports, for virologically confirmed SARS2 infection, or for solid clinical signs and symptoms of 20 COVID. We annotated these samples and selected those with dpo ≥14, which we expected to have developed an IgG response, as condition-positive (n=19). To avail of condition-positives from the cohort of blood donors, 51 samples from convalescent individuals with PCR-confirmed SARS2 infection recruited for a plasmapheresis study were included. Importantly, we screened 3,815 prepandemic samples (condition-negatives) to determine potentially unspecific results, e.g. 25 due to cross-reactivity with other coronaviruses. For the BDS cohort, we enriched the conditionnegatives with 1,400 samples from December 2019 and January 2020 to increase the numbers of the assumed negatives and to obtain a more reliable baseline. Using the distributions of the condition negatives and the condition positives, we computed the posterior probability (i.e. the probability of an individual to be seropositive as modeled via the distribution of the known condi-30 tion-negatives and known condition-positives) for all data points (see Fig. S1A, B) . The respective ROC curves were then plotted (Fig. S1E, F) . At 100% specificity, we identified 18/19 of the annotated true positives for the USZ (Fig. S1E) and 38/51 annotated true positives for the BDS cohort . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted June 2, 2020. . https://doi.org/10.1101/2020.05.31.20118554 doi: medRxiv preprint (Fig. S1F) . For the BDS cohort, the sensitivity increased rapidly with a slight decrease in specificity (at a false-positive-rate of 0.001, we identified 45/51 condition positives). We then applied this model to estimate the prevalence on the population level. No substantial shift above baseline was inferred for samples screened from January, February, and March 2020 ( Fig. 2C and Fig.   S1G , USZ cohort). A sudden increase in prevalence manifests in April (multivariate Gaussian: 5 0.8% (CI95%: 0.2%-1.4%) and multivariate t distribution: 0.4% (CI95%: 0.0%-0.8%)) and May 2020 (multivariate Gaussian: 1.3% (CI95%: 0.8%-1.8%) and multivariate t distribution: 0.9% (CI95%: 0.6%-1.4%)), in accordance with the virologically and clinically reported rise in SARS2 infections in these months. The assembly of healthy blood donors showed a comparable time course of seroconvertion, with the prevalence approximating 1% in April (multivariate Gaussian: 10 1.1% (CI95%: 0.6%-1.6%) and multivariate t distribution: 1.0% (CI95%: 0.5%-1.4%)) ( Fig. 2C and Using QDA, the posterior probability was calculated assuming a multivariate Gaussian distribution. C. Prevalence of SARS2 seropositivity in prepandemic (before 2019) and co-pandemic samples (from December 2019 to May 2020) estimated using the posterior probabilities from the multivariate Gaussian distribution. Bar shows 95% CI. D. TRABI reproducibility was assessed using duplicates run in pairs of independent assay plates. E. To assess potential cross-reactivity of SARS2 seropositive individuals, we tested 210 high-scoring samples and 122 random samples for binding to the RBD of SARS1. SARS2 RBD binders with a high posterior probability (same color map as in B) segregated within the higher anti-SARS1-RBD titers.

. CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted June 2, 2020. Antibodies against the RBD of SARS-CoV (henceforth termed SARS1) have shown to be able to 20 bind to the RBD of SARS2 [11] . Here we included the SARS1 RBD to examine whether individuals with strong binding properties to the SARS2 RBD display cross-reactiv-25 ity. For visualization, we formed groups that reflect the binding propensity of individuals to SARS2 RBD (<1.5; 1.5-2, > 2.5) and indicated their respective QDA-derived posterior probability. For individuals with SARS2 RBD < 2, a small fraction show binding to SARS1 RBD at -log(EC50) > 2 ( Fig. 2E) . However, those with strong binding properties to SARS2 RBD (> 2.5) cluster at high values for SARS1 RBD, indicating that some anti-SARS2 RBD antibodies are likely cross-reactive 30 to SARS1 RBD.

In summary, TRABI identified first cases of SARS2 seroconversion in April 2020, consistent with first infections reported in the Zurich area towards the end of February 2020. While data obtained . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 2, 2020. . https://doi.org/10.1101/2020.05.31.20118554 doi: medRxiv preprint from healthy individuals suggest that around 1% of blood donors have been infected in the absence of clear clinical symptoms, the serological prevalence is about 5-fold higher than RT-qPCR confirmed cases for the same time point. However, these data indicate that seroconversion within the greater area of Zurich is still exceedingly rare and very far from herd immunity.

Clinical and demographic characteristics of serologically confirmed SARS2 infected hospital pa-5 tients and healthy donors.

The USZ cohort had a median age of 56 (41 -69) years, with a median of those with an increased posterior probability (> 0.5) of 59 (51 -63) ( Fig. 3A and Table S1 ). The BDS cohort had a median age of 43 (29 -54), while those individuals with posterior probability > 0.5 had a median age of 39 (29 -53) ( Fig. 3B and Table S1 ). Fig. 3C shows the age pyramid of the inhabitants of the Canton 10 of Zurich [12] , as a comparison to our cohorts. The blood of USZ patients was drawn in 38 clinical departments ( Fig. 3D ) of which 16 treated patients that we consider SARS2-positive based on a posterior probability > 0.5. In absolute counts, most SARS2-positive samples were obtained from Infectiology, followed by Internal Medicine, Cardiology and Emergency. The wide range of departments that sees SARS2-infected patients is indicative that SARS2 seropositive patients do 15 not solely enter the hospital for the treatment of COVID-19 but for any condition that requires the attention of a USZ physician. Lastly, seropositivity can be found across all age groups and in both genders, with more male individuals affected in the USZ and BDS cohorts (Fig. 3A , B, Table S1 ).

More time is needed to track and correlate SARS2 seropositivity with disease susceptibility.

Prevalence of anti-SARS2 antibodies in prepandemic samples. 20 5'215 prepandemic plasma samples (2'719 USZ hospital patients and 2'496 healthy BDS donors) were examined for the presence of cross-reactive antibodies against S, RBD and NC of SARS2.

Several individuals had a strong antibody response against a single antigen and an absence of binding to other antigens (Fig. S1A, B) . We then directly compared prepandemic and co-pandemic samples in the USZ cohort on the basis of single antigens and their respective posterior 25 probabilities. When focusing on samples with high values for single assays, we observed an enrichment of high posterior probabilities in pandemic but not in the prepandemic group (Fig. 4A ).

Among samples with individual -log(EC50) values above 2 in May, 66% (S), 82% (RBD), and 17%

(NC) had a posterior probability above 0.5. At the same time, no sample with an individual assay level above 2 had a posterior probability above 0.5 in the prepandemic samples. This enrichment 30 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 2, 2020. . https://doi.org/10.1101/2020.05.31.20118554 doi: medRxiv preprint is suggestive of a substantial performance improvement when using the combined metric in the USZ cohort.

We then compared the immunochemical properties of two prepandemic samples with high binding to S to two samples of confirmed COVID (COVID 1 and 2, see annotation in Fig. 4A ). The COVID samples, but not the prepandemic samples, recognized in Western blots the S, RBD and NC 5 antigens of SARS2 expressed by Expi293F (Fig. 4B) . Additional ELISAs performed on the same samples confirmed the initial findings (Fig 4C) including binding to the RBD in COVID but not in Posterior probability calculated using the Gaussian distribution, visualized for single antigens for prepandemic samples vs. USZ samples drawn in May 2020. Prepandemic samples exhibited a low posterior probability as they typically react against single antigens, leading to low rankings in a composite metric. For further testing, comparative samples were chosen from the prepandemic era and from May 2020. B. Western Blot analysis of two samples from May 2020 ("COVID 1" and "COVID 2") and two prepandemic samples ("prepandemic 1" and "prepandemic 2"). Anti-his-tag antibody was included as a positive control. Lane 1 = non-transfected Expi293F cell lysate; Lane 2 = Expi293F cell lysates expressing his-tagged S, NC and RBD proteins. Black arrows: S; blue arrows: NC. Uncropped images in Fig. S4 . C. ELISA assays on the same samples as in B, using SARS2 S, NC, RBD and NSP1 as well as control proteins (BSA, CMV pp65). D. Soluble RBD or S were allowed to engage with plasma (same samples as in B and C), and ELISA was then performed with immobilized RBD or S. Data points represent averages of duplicates. Soluble antigens suppressed the ELISA signal in the COVID samples but not in the prepandemic sample, showing that the antibodies present in the latter had low affinities for the SARS2 targets.

. CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 2, 2020. . https://doi.org/10.1101/2020.05.31.20118554 doi: medRxiv preprint prepandemic samples. However, COVID samples showed reactivity in Western Blot against both S and NC, but not against RBD (Fig. 4B) , suggesting that they recognized conformational epitopes lost upon boiling and SDS denaturation.

To probe the specificity of the findings, we also carried out competitive ELISAs on 3 out of 4 specimens including prepandemic and COVID patients. First, we determined plasma concentra-5 tions close to the EC50. Then we pre-incubated appropriately diluted samples with various concentrations of S and RBD (0.04-88 and 0.7-1350 nM, respectively). Samples were then transferred onto ELISA plates coated with S, RBD, and NC. The concentration-dependent displacement of the measured optical density was then visualized (Fig. 4D) . We found that both soluble S and the RBD caused a concentration-dependent depletion of the RBD in COVID samples, but 10 not in a prepandemic sample. The prepandemic sample displayed no competition, suggesting that its reactivity was due to high concentrations of low-affinity antibodies cross-reacting with SARS2 S.

TRABI enabled the identification of 26 blood donors with no apparent signs of SARS2 infection 15 ( Fig. 2B, C) . They had no reported symptoms despite clear serological indications of past infection, as confirmed by ELISA (Fig. 5A) . In a comparative approach, we investigated IgG and IgA antibodies to S, RBD, and NC as well as responses to multiple control antigens, in four asymptomatic blood donors and 4 convalescent individuals recruited to the BDS for a plasmapheresis study. We observed binding of IgG antibodies in asymptomatic and convalescent individuals 20 against S, RBD, and NC, with usually lower IgA titers. No binding against the SARS2 non-structural-protein 1 (NSP1), or against bovine serum albumin (BSA) was observed. We confirmed these findings by using the samples of the asymptomatic and convalescent individuals as primary antibodies in Western Blot and detected bands for both S and the NC in the Expi293 cells overexpressing the viral proteins but not in the Expi293 control lysate (Fig. 5B) . 25

To obtain a rough estimate of the clonality and epitope specificity of the immune response raised against the S protein, we conducted an ELISA-based soluble antigen competition. Competition with the RBD lead to a decrease in ELISA signal for RBD but not for S or NC ( Fig. 5C and Fig.   S3A ). Conversely, competition with S decreased the signal for both S and the RBD (Fig. 5C) ,

suggesting the presence of antibodies targeting multiple S epitopes, including RBD. Therefore, 30 the immune response against S was polyclonal.

. CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 2, 2020. . https://doi.org/10.1101/2020.05.31.20118554 doi: medRxiv preprint . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 2, 2020. . https://doi.org/10.1101/2020.05.31.20118554 doi: medRxiv preprint

The high-throughput pipeline for SARS2 serology described above has enabled us to study a large cohort over a time span of six months, with up to 1'000 more samples being tested every day. In view of the critique levelled at past serological studies [1, 13] , we have gone to great lengths to assess and validate our technology. For the initial assay calibration, sensitivity was 5 measured using a panel of clinically and RT-qPCR confirmed SARS2 sera (n=56) at various time points after onset of clinical signs and symptoms and 90 negative controls. A blinded comparison with commercial test kits showed that our approachcombining three individual assays into one single scorewas suitable for large-scale epidemiologic studies.

A key question for handling the current SARS2 pandemic is the true rate of people who have 10 already contracted the virus. As a proxy for the estimation of the true prevalence in the population of the greater area of Zurich, we have used two independent cohorts: (1) suggests that combining the metrics did indeed lead to a power gain. One drawback of modeling the multivariate distribution of antigen measurements directly, is that deviation from modeling assumption are harder to detect and correct in a multivariate situation. We explored the robustness-20 to modeling-assumption by modeling the condition negative samples, either with a multivariate Gaussian or multivariate t distribution and saw moderate drops in predicted prevalence when going from a Gaussian to t distribution (11% for BDS and 30% for USZ). An alternative would be to focus on linear methods that enable the data to be projected onto one dimension first, such as linear discriminant analysis, allowing the estimate of prevalence from a univariate mixture distri-25 bution. The extent of our sampling, however, bolsters our confidence in the representability and validity of our results.

We find that in both cohorts, the prevalence of seropositives continues to linger around 1%. Each of our cohorts entail intrinsic biases. On the one hand, the USZ cohort consists mostly of individuals suffering from diseases, some of which may be a consequence of SARS2 infections. On the 30 other hand, individuals with acute infections are typically excluded from donating blood. As a consequence, the BDS cohort may be biased against individuals who may have experienced COVID symptoms and refrained from donating. Because of these fundamental differences in the . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 2, 2020. . https://doi.org/10.1101/2020.05.31.20118554 doi: medRxiv preprint composition of the USZ and BDS cohorts, we find it particularly relevant that both cohorts converge towards a prevalence around 1%. This observation undescores the presumption that the prevalence reported here is truly representative of the population under study.

The low prevalence of SARS2 immunity is unexpected for many reasons. The initial trajectory of the disease with high replicative numbers had engendered suggestions that a large swath of the 5 population might have encountered the virus and developed humoral immunity. This idea is now soundly refuted. The 1% prevalence is even more surprising when considering that (1) Switzerland borders on Northern Italy whose prevalence of infection was reported to reach 43% in healthcare workers [14] , (2) Ticino and Western Switzerland were profoundly affected by the pandemic, and (3) no travel restrictions were imposed between Ticino and Northern Switzerland. 10

When set in relation to the regional numbers of RT-qPCR-positive cases, our cohort-based estimates of the seroprevalence (1% in early May 2020) are in line with those of more affected regions of Switzerland, like Geneva (seroprevalence around 9.7%, end of April 2020 [15] ) and are about 5-10 times higher than the respective incidence of overt COVID [16] .

A recent publication [17] has shown pre-existing anti-SARS2 antibodies in unexposed humans. 15

Our affinity determinations and immunoblots, however, point to fundamental differences between prepandemic seropositivity and the immune responses of SARS2-infected individuals. While the latter consistently showed high-affinity responses that were clearly visible in Western blotting, the few seropositive prepandemic sera were mostly negative in Western blotting, and equilibrium displacement ELISA of one prepandemic plasma sample suggested a much lower affinity despite 20 similar antibody EC50 titers. We conclude that any immune response in uninfected individuals, whether it represents cross-reactivity with common-cold coronaviruses or something else, is of inferior quality and may be less likely to be protective.

Our population-wide screen allows us to address several crucial questions that have been controversially discussed. What is the frequency of truly asymptomatic cases? What is the complete 25 spectrum of clinical signs and symptoms with which SARS2-infected individuals present? Many SARS2 patients present with monosymptomatic anosmia, and it is conceivable that other illnesses may represent hitherto unrecognized signs of SARS2 infection. Stratifying the results of our screens, e.g. by referencing clinic and by ICD codes and laboratory values of the patients, will become increasingly important in the years to come, e.g. to protect those at risk, to evaluate 30 immune defenses and their possible waning, and to plan vaccination campaigns.

Our study is conceived as a long-term exercise which, given appropriate funding, will be continued for the next several years. In addition to allowing precise monitoring of the population, it will also . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 2, 2020. . https://doi.org/10.1101/2020.05.31.20118554 doi: medRxiv preprint enable the determination of titer decays in seropositive individuals as a function of demographic indicators and of comorbidities. However, there are societal concerns linked to antibody testing, and scientists must not downplay them. Serology is a powerful medical and epidemiological instrument, but it can also be misused to stratify the workforce, to discriminate against the nonimmune, and even for far more nefarious deeds. Let's study immune responses, but let's not 5 create a dystopian society based on them.

. CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 2, 2020. . https://doi.org/10.1101/2020.05.31.20118554 doi: medRxiv preprint 

In order to test the samples for the presence of IgG antibodies directed against SARS-CoV-2 20 antigens, high-binding 1536-well plates (Perkin Elmer, SpectraPlate 1536 HB) were coated with 1 µg/mL S or RBD or NC in PBS at 37 °C for 1 h, followed by 3 washes with PBS-T (using Biotek El406) and by blocking with 5% milk in PBS-T (using Biotek MultifloFX peristaltic pumps) for 1.5 h. Three µL plasma, diluted in 57 µL sample buffer (1% milk in PBS-T), were dispensed at various volumes (from 1200 nL down to 2.5 nL) into pre-coated 1536-well plates using contactless dis-25 pensing with an ECHO 555 Acoustic Dispenser (Labcyte/Beckman Coulter). Sample buffer was filled up to 3 uL total well volume using a Fritz Gyger AG Certus Flex dispenser. Thereby, dilution curves ranging from plasma dilutions 1:50 to 1:6400 were generated (eight dilution points per patient plasma sample). After the sample incubation for 2 h at RT, the wells were washed five times with wash buffer and the presence of IgGs directed against above-defined SARS-CoV-2 30 antigens was detected using an HRP-linked anti-human IgG antibody (Peroxidase AffiniPure Goat Anti-Human IgG, Fcγ Fragment Specific, Jackson, 109-035-098, at 1:4000 dilution in sample buffer). The incubation of the secondary antibody for one hour at RT was followed by three . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 2, 2020. . https://doi.org/10.1101/2020.05.31.20118554 doi: medRxiv preprint washes with PBS-T, the addition of TMB, an incubation of three minutes at RT, and the addition of 0.5 M H2SO4 (both steps with Biotek MultifloFX syringe technology). The final well volume for each step was 3 µL. The plates were centrifuged after all dispensing steps, except for the addition of TMB. The absorbance at 450 nm was measured in a plate reader (Perkin Elmer, EnVision) and the inflection points of the sigmoidal binding curves were determined using the custom designed 5 fitting algorithm described below.

We used the following commercial tests for the detection of anti-SARS-SARS2 antibodies in 56 plasma samples of 27 patients who were diagnosed by RT-PCR to be infected by SARS-SARS2 as well as 83-90 plasma samples which were collected before December 2019 and, hence, before 10 the start of the COVID19 pandemics: The double-antigen sandwich electro-chemiluminescence immunoassay from Roche diagnostics (Rotkreuz, Switzerland) was performed with the E801 of the COBAS8000® system (Roche diagnostics, Rotkreuz, Switzerland). The test detects any antibody against the nucleocapsid antigen. The fully automated LIAISON® SARS-CoV-2 chemiluminescence immunoassay from DiaSorin (Saluggia, Italy) detects IgG against the S1/S2 antigens. 15

The SARS-CoV-2 chemiluminescent microparticle immunoassay from Abbott (Abbott Park, IL, USA) detects IgG against the nucleocapsid antigen and was performed on an Architect™ analyser. Two ELISAs from EUROIMMUN (Lübeck, Germany) detect IgA or IgG against the S1 anti- . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 2, 2020. Therefore, we assign sample to group 1 if log ( | =1 ( )) + log ( 1 ) > log ( | =0 ( )) + log ( 0 ),

. CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 2, 2020. . https://doi.org/10.1101/2020.05.31.20118554 doi: medRxiv preprint And to group 0 otherwise. To set the prior, one option is to take just the mean of the group sizes. However, this is not an ideal option in our case, where we have an additional samples with unknown serostatus to classify: The prevalence in the samples with known serostatus might deviate substantially from the prevalence in population with unknown serostatus. We therefore estimate 1 directly from the data of unknown serostatus using a simple expectation maximization 5 scheme. Proceeding in an iterative fashion, from a given estimate 1 , we define the posterior (E step):

Then, we update our estimate of 1 (M step):

After convergence, this yields our estimate of the positive serostatus prevalence in the samples. 15

Note that the sample ordering according to this classifier is independent of the prior and therefore has no impact on an analysis via ROC curves. Further, note that evaluating QDA via ROC analysis, an out of sample scheme should be employed to avoid biased estimates of performance; we chose 10-fold cross-validation throughout. Lastly, note that the strategy does not critically depend on the normality assumption but just requires an estimate for the density functions, | = ( ). 20

Even nonparametric estimates could be an option. We either restricted | = both to multivariate Gaussian or set | =0 to a multivariate t with estimated degrees of freedom while still modeling | =1 as Gaussian. For degrees of freedom estimation, we used the R package QRM. 95% confidence intervals were derived by bootstrap drawing 1000 bootstrap samples.

For the validation screen, we picked 60 and 150 samples from BDS and USZ respectively, that had the highest average values when summing -logEC50 for both Spike and RBD. Additionally, we added 52 and 70 randomly selected prepandemic samples for the BDS and the USZ cohort respectively. We supplemented the three antigens used in the first screen (NC, S, RBD of SARS-. CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 2, 2020. . https://doi.org/10.1101/2020.05.31.20118554 doi: medRxiv preprint SARS2) with a SARS-CoV RBD antigen. Unlike for the primary screen, we ran all samples in duplicates spread over two independent plates.

The proteins were produced and purified at different sites in Zurich (CH), Oxford (UK), Lausanne (CH), and Yale University (USA). 5

Oxford, SGC. Recombinant proteins were purified as reported previously with small modifications [6, 18] . Mammalian expression vectors containing secreted, codon-optimized SARS-CoV-2 S (pHL-Sec [19] ; aa. 1-1208, C-terminal 8His-Twin-Strep) and RBD (pOPINTTGNeo; aa. 330-532, C-terminal 6His) were transiently transfected with linear PEI into Expi239 TM cells cultured in roller bottles in FreeStyle 293 media. Cell culture media was harvested after 3 days at 37°C for RBD or Peak fractions were pooled and the protein concentration was determined by 280 nm absorbance . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 2, 2020. . is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 2, 2020. . https://doi.org/10.1101/2020.05.31.20118554 doi: medRxiv preprint tagged S, His-tagged NC or His-tagged RBD domain were lysed in 0,1% Triton X-100/PBS. Total protein content in the cellular fraction was quantified using bicinchoninic protein assay (Pierce BCA Protein Assay Kit, ThermoFisher). For Western Blotting, 30 µg of ECD-expressing lysate, 10 µg of NC-expressing lysate and 10 µg of RBD-expressing lysate were loaded all in the same well of NU-PAGE 4-12% Bis-Tris gels (ThermoFisher). 50 µg of non-transfected cell lysate were 5 loaded as negative control. Gels were run at a constant voltage (150 V) in MES running buffer for 50 minutes, then transferred onto PVDF membrane with a dry transfer system (iBlot 2 Gel Transfer Device, ThermoFisher). The membranes were blocked with 5% SureBlock (Lubio Science) for 1 hour at room temperature, and then incubated overnight with a 1:100 dilution of patients' plasma in 1% SureBlock, at 4 degrees. The day after, membranes were washed four times with PBS-T 10 and incubated for 1 hours with an anti-human secondary antibody, HRP-conjugated, diluted 1:10000 in 1% SureBlock. The membranes were then washed four times with PBS-T and acquired using Immobilon Crescendo HRP Substrate (Merck Millipore) and Fusion SOLO S imaging system (Vilber). As a positive control, one membrane was incubated overnight with mouse anti-Histag antibody (ThermoFisher, dilution 1:10000 in 1% SureBlock) and subsequently with anti-mouse 15 secondary antibody, HRP-conjugated (Jackson, dilution 1:10000 in 1% SureBlock).

To perform competitive ELISAs, high-binding 384-well plates (Perkin Elmer, SpectraPlate 384 HB) were coated with 1 ug/mL S or RBD or NC in PBS at 37°C for 1 h, followed by 3 washes with . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 2, 2020. . https://doi.org/10.1101/2020.05.31.20118554 doi: medRxiv preprint (USZ) for their continuous help with hospital data, and Didier Trono for helpful insights and discussions. Above all, we are grateful to all blood donors and hospital patients for helping us conduct this study. 

TPJK is a member of the board of directors of Fluidic Analytics. AA is a member of the board of directors of Mabylon AG which has funded antibody-related work in the Aguzzi lab in the past. All 15 other authors declare no competing interests.

The raw data underlying this study will be made available upon reasonable request. The biobank samples are limited and were exhausted in several instances. Therefore, while we will make efforts to provide microliter amounts of samples to other researchers, their availability is physically 20 limited.

. CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 2, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 2, 2020. 

COVID-19 Antibody Seroprevalence

Variation in False-Negative Rate of Reverse Transcriptase Polymerase Chain Reaction-Based SARS-CoV-2 Tests by Time Since Exposure

Temporal dynamics in viral shedding and transmissibility of COVID-19

A serological assay to detect SARS-CoV-2 seroconversion in humans

Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease

SARS-CoV-2 Seroconversion in Humans: A Detailed Protocol for a Serological Assay, Antigen Production, and Test Setup

Increasing the throughput of crystallization condition screens: Challenges and pitfalls of acoustic dispensing systems

Cryo-EM structure of the SARS coronavirus spike glycoprotein in complex with its host cell receptor ACE2

Estimating the burden of SARS-CoV-2 in France

Fundamental principles of epidemic spread highlight the immediate need for large-scale serological surveys to assess the stage of the SARS-CoV-2 epidemic

Identification of SARS-CoV RBD-targeting monoclonal antibodies with 25 cross-reactive or neutralizing activity against SARS-CoV-2

Alter der Wohnbevoelkerung der Stadt Zuerich

Infection fatality rate of SARS-CoV-2 infection in a German community with a super-spreading event

IgG serology in health care and administrative staff populations from 7 hospital representative of different exposures to SARS-CoV-2 in Lombardy

Repeated seroprevalence of anti-SARS-CoV-2 IgG antibodies in a population-based sample from Geneva

Pre-existing and de novo humoral immunity to SARS-CoV-2 in humans

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

A time-and cost-efficient system for high-level 45 protein production in mammalian cells

All authors wish to thank their entire teams for support in the lab. We thank Linda Irpinio for help in the lab. We thank Vishalini Emmenegger (ETH Zurich) for insightful advice and kind help with illustrations. We are grateful to Elisabeth J. Rushing (USZ) for proofreading the manuscript. We thank Guido Bucklar, Michael Fetzer, Patrick Hirschi, Katie Kalt, Karin Edler and Roland Naef